Co-Target(s) Information

Content Navigation (  All   None )                                      
Target General Information
Co-Targets of This Target
References
Target General Information  Top
Target ID T67849 Target Info
Target Name PI3-kinase delta (PIK3CD)
Synonyms
PtdIns-3-kinase subunit p110-delta; PtdIns-3-kinase subunit delta; Phosphoinositide 3-kinase delta; Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, delta isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta; PI3Kdelta; PI3K-delta; PI3-kinase subunit delta; PI3-kinase p110 subunit delta; P110delta
    Click to Show/Hide
Target Type Successful Target
Gene Name PIK3CD
Biochemical Class Kinase
UniProt ID
PK3CD_HUMAN
Co-Targets of This Target  Top
Co-Target Name PI3-kinase alpha (PIK3CA) Successful Target
UniProt ID PK3CA_HUMAN
Gene Name PIK3CA
Synonyms
p110alpha; Serine/threonine protein kinase PIK3CA; PtdIns3kinase subunit p110alpha; PtdIns3kinase subunit alpha; PtdIns-3-kinase subunit p110-alpha; PtdIns-3-kinase subunit alpha; Phosphoinositide3kinase catalytic alpha polypeptide; Phosphoinositide-3-kinase catalytic alpha polypeptide; Phosphatidylinositol 4,5bisphosphate 3kinase catalytic subunit alpha isoform; Phosphatidylinositol 4,5bisphosphate 3kinase 110 kDa catalytic subunit alpha; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha; PI3kinase subunit alpha; PI3Kalpha; PI3K-alpha; PI3-kinase subunit alpha
    Click to Show/Hide
Representative Drug(s) BAY 80-6946 Drug Info IC50 = 0.5 nM Click to Show More [1]
2 PA-799 Drug Info IC50 = 14 nM [3]
3 Buparlisib Drug Info IC50 = 20 nM [4]
4 Idelalisib Drug Info IC50 = 177.2 nM [10]
Co-Target Name PI3-kinase gamma (PIK3CG) Successful Target
UniProt ID PK3CG_HUMAN
Gene Name PIK3CG
Synonyms
p120-PI3K; p110gamma; Serine/threonine protein kinase PIK3CG; PtdIns-3-kinase subunit p110-gamma; PtdIns-3-kinase subunit gamma; PtdIns-3-kinase p110; Phosphoinositol-3 kinase; Phosphoinositide-3-kinase catalytic gamma polypeptide; Phosphoinositide 3-Kinase gamma; Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit, gamma isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit gamma; PI3Kgamma; PI3K-gamma; PI3K; PI3-kinase subunit gamma; PI3-kinase p110 subunit gamma
    Click to Show/Hide
Representative Drug(s) BAY 80-6946 Drug Info IC50 = 0.7 nM Click to Show More [1]
2 IPI-145 Drug Info IC50 = 2 nM [2]
3 RP6530 Drug Info IC50 = 33 nM [5]
4 PA-799 Drug Info IC50 = 36 nM [6]
5 Idelalisib Drug Info IC50 = 60 nM [8]
6 Umbralisib Drug Info IC50 ~ 120 nM [5]
7 Buparlisib Drug Info IC50 = 256 nM [1]
8 AMG 319 Drug Info IC50 = 850 nM [11]
Co-Target Name Serine/threonine-protein kinase mTOR (mTOR) Successful Target
UniProt ID MTOR_HUMAN
Gene Name MTOR
Synonyms
Target of rapamycin; TOR kinase; Rapamycin target protein 1; Rapamycin target protein; Rapamycin and FKBP12 target 1; RAPT1; RAFT1; Mechanistic target of rapamycin; Mammalian target of rapamycin; FRAP2; FRAP1; FRAP; FKBP12-rapamycin complex-associated protein; FKBP-rapamycin associated protein; FK506-binding protein 12-rapamycin complex-associated protein 1
    Click to Show/Hide
Representative Drug(s) BAY 80-6946 Drug Info IC50 = 45 nM Click to Show More [7]
2 Buparlisib Drug Info IC50 = 94 nM [9]
3 Idelalisib Drug Info IC50 ~ 1000 nM [12]
Co-Target Name PI3-kinase beta (PIK3CB) Clinical trial Target
UniProt ID PK3CB_HUMAN
Gene Name PIK3CB
Synonyms
p110beta; PtdIns3kinase subunit p110beta; PtdIns3kinase subunit beta; PtdIns-3-kinase subunit p110-beta; PtdIns-3-kinase subunit beta; Phosphatidylinositol 4,5bisphosphate 3kinase catalytic subunitbeta isoform; Phosphatidylinositol 4,5bisphosphate 3kinase 110 kDa catalyticsubunit beta; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit beta; PIK3C1; PI3kinase subunit beta; PI3Kbeta; PI3K-beta; PI3-kinase subunit beta
    Click to Show/Hide
Representative Drug(s) BAY 80-6946 Drug Info IC50 = 3.7 nM Click to Show More [1]
2 IPI-145 Drug Info IC50 = 85 nM [13]
3 PA-799 Drug Info IC50 = 120 nM [3]
4 Idelalisib Drug Info IC50 = 120.1 nM [14]
5 Buparlisib Drug Info IC50 = 165.96 nM [15]
Co-Target Name PI3K p110 alpha/p85 alpha (PIK3CA/PIK3R1) Co-Target
UniProt ID PK3CA_HUMAN-P85A_HUMAN
Gene Name PIK3CA-PIK3R1
Representative Drug(s) BAY 80-6946 Drug Info IC50 = 0.11 nM Click to Show More [16]
2 Buparlisib Drug Info IC50 = 11 nM [17]
3 IPI-145 Drug Info IC50 = 400 nM [19]
4 Idelalisib Drug Info IC50 = 800 nM [13]
Co-Target Name PI3K p110 beta/p85 alpha (PIK3CB/PIK3R1) Co-Target
UniProt ID PK3CB_HUMAN-P85A_HUMAN
Gene Name PIK3CB-PIK3R1
Representative Drug(s) BAY 80-6946 Drug Info IC50 = 4.57 nM Click to Show More [16]
2 IPI-145 Drug Info IC50 = 8 nM [2]
3 Buparlisib Drug Info IC50 = 234 nM [17]
4 Idelalisib Drug Info IC50 = 293 nM [2]
Co-Target Name PI3K-gamma/PI3K regulatory subunit 5 (PIK3CG-PIK3R5) Co-Target
UniProt ID PK3CG_HUMAN-PI3R5_HUMAN
Gene Name PIK3CG-PIK3R5
Representative Drug(s) Buparlisib Drug Info IC50 = 129 nM [18]
Co-Target Name PI3 kinase subunit beta-PI3 kinase regulatory subunit beta (PIK3CB-PIK3R2) Co-Target
UniProt ID PK3CB_HUMAN-P85B_HUMAN
Gene Name PIK3CB-PIK3R2
Representative Drug(s) Idelalisib Drug Info IC50 = 579 nM [20]
Co-Target Name Phosphatidylinositol 3-kinase catalytic subunit type 3 (PIK3C3) Co-Target
UniProt ID PK3C3_HUMAN
Gene Name PIK3C3
Synonyms
PI3-kinase type 3; PI3K type 3; PtdIns-3-kinase type 3; Phosphatidylinositol 3-kinase p100 subunit; Phosphoinositide-3-kinase class 3; hVps34
    Click to Show/Hide
Representative Drug(s) Idelalisib Drug Info IC50 = 980 nM [5]
Co-Target Name Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta (PIK3C2B) Co-Target
UniProt ID P3C2B_HUMAN
Gene Name PIK3C2B
Synonyms
PI3K-C2-beta; PtdIns-3-kinase C2 subunit beta; C2-PI3K; Phosphoinositide 3-kinase-C2-beta
    Click to Show/Hide
Representative Drug(s) Idelalisib Drug Info IC50 ~ 1000 nM [21]
References  Top
REF 1 Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer. Eur J Med Chem. 2019 Dec 1;183:111718.
REF 2 Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kgamma-PI3Kdelta Dual Inhibitors. J Med Chem. 2019 May 23;62(10):4936-4948.
REF 3 Small molecules targeting phosphoinositide 3-kinases. Medchemcomm. 2012;3:1337-55.
REF 4 Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases. J Med Chem. 2019 Aug 8;62(15):6992-7014.
REF 5 Evolution of PI3Kgamma and delta Inhibitors for Inflammatory and Autoimmune Diseases. J Med Chem. 2019 May 23;62(10):4783-4814.
REF 6 Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799. Bioorg Med Chem Lett. 2011 Mar 15;21(6):1767-72.
REF 7 Class 1 PI3K Clinical Candidates and Recent Inhibitor Design Strategies: A Medicinal Chemistry Perspective. J Med Chem. 2019 May 23;62(10):4815-4850.
REF 8 Conformationally restricted quinazolone derivatives as PI3Kdelta-selective inhibitors: the design, synthesis and biological evaluation. Med. Chem. Commun. 2019;10:413-420.
REF 9 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology. J Med Chem. 2017 Sep 14;60(17):7524-7538.
REF 10 Synthesis and biological evaluation of 4-(piperid-3-yl)amino substituted 6-pyridylquinazolines as potent PI3Kdelta inhibitors. Bioorg Med Chem. 2019 Oct 1;27(19):115035.
REF 11 Discovery and in Vivo Evaluation of the Potent and Selective PI3Kdelta Inhibitors 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-6-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-0687) and 2-((1S)-1-((6-Amino-5-cyano-4-pyrimidinyl)amino)ethyl)-5-fluoro-N-methyl-3-(2-pyridinyl)-4-quinolinecarboxamide (AM-1430). J Med Chem. 2016 Aug 11;59(15):7252-67.
REF 12 Discovery of 1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-ones based novel, potent and PI3Kdelta selective inhibitors. Bioorg Med Chem Lett. 2019 Jun 1;29(11):1313-1319.
REF 13 Targeting the immunity protein kinases for immuno-oncology. Eur J Med Chem. 2019 Feb 1;163:413-427.
REF 14 Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kdelta) inhibitors. Bioorg Med Chem. 2018 May 1;26(8):2028-40.
REF 15 Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy. J Med Chem. 2020 Jan 9;63(1):122-139.
REF 16 Design, Synthesis, and Biological Evaluation of Imidazo[1,2- a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors. J Med Chem. 2020 Mar 26;63(6):3028-3046.
REF 17 Discovery of an Orally Bioavailable Dual PI3K/mTOR Inhibitor Based on Sulfonyl-Substituted Morpholinopyrimidines. ACS Med Chem Lett. 2018 Jun 25;9(7):719-724.
REF 18 Design, Synthesis, and Biological Evaluation of Substituted Pyrimidines as Potential Phosphatidylinositol 3-Kinase (PI3K) Inhibitors. J Med Chem. 2016 Aug 11;59(15):7268-74.
REF 19 Piperidinyl-embeded chalcones possessing anti PI3Kdelta inhibitory properties exhibit anti-atopic properties in preclinical models. Eur J Med Chem. 2018 Oct 5;158:405-413.
REF 20 Discovery of fluoroquinolone derivatives as potent, selective inhibitors of PI3K gamma. Med. Chem. Commun. 2015;6:2029-2035
REF 21 Class II Phosphoinositide 3-Kinases as Novel Drug Targets. J Med Chem. 2017 Jan 12;60(1):47-65.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.